Metformin — life begins at 50

Abstract

Get full access to this article

View all access options for this article.

References

Bailey CJ , Day C. Metformin: its botanical background. Practical Diabetes Int 2004;21:115-17.

Hadden DR Goat's rue - French lilac - Italian fitch - Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edin 2005;35:258-60.

Joslin EP Proceedings of the nineteenth annual meeting of the American Society for Clinical Investigation, Atlantic City, New Jersey, USA, May 2, 1927. J Clin Invest 1927;4:435-6.

Sterne J. Du Nouveau dans les antidiabétiques. La NN diméthylamino guanyl guanidine (N.N.D.G.). Maroc Med 1957;36:1295-6.

Rambert P. , Canivet J. , Quichaud F. , Spitz B. Treatment of diabetes mellitus with NNdimethil-diguanide. La Medecin en France. 1961;September:29-37.

Shaw RJ , Lamia KA , Vasquez D. et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310:1642-6.

UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

Dormandy JA , Charbonnel B. , Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit-Azone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.

Kao J. , Tobis J. , McClelland RL et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004;93:1347-50.

10.

Scarpello JH Improving survival with metformin: the evidence base today. Diabetes Metab 2003;29:6S36-6S43.

11.

Sgambato S. , Varricchio M. , Tesauro P. , Passariello N. , Carbone L. L'utilisation de la metformin dans la cardiopathie ischemique. Clin Ter 1980;94:77-85.

12.

Mather KJ , Verma S. , Anderson TJ Improved endothelial function with metformin in type 2 diabetes mellitus . J Am Coll Cardiol 2001;37:1344-50.

13.

Katakami N. , Yamasaki Y. , Hayaishi-Okano R. et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intimamedia thickness in subjects with type 2 diabetes . Diabetologia 2004;47:1906-13.

14.

Garber AJ , Duncan TG , Goodman AM et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7.

15.

Fujioka K. , Brazg RL , Raz I. et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab 2005;7:28-39.

16.

Saenz A. , Fernandez-Esteban I. , Mataix A. et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; CD002966.

17.

Kahn SE , Haffner SM , Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.. N Engl J Med 2006;355:2427-43.

18.

Charbonnel B. , Karasik A. , Liu J. , et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.

19.

DeFronzo RA , Ratner RE , Han J. , et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.

20.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med 2002;346:393-403.

21.

Ramachandran A. , Snehalatha C. , Mary S. et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) . Diabetologia 2006; 49:289-97.

22.

Wenying Y. , Lixiang L. , Jinwu Q. , et al. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3 year multicentral prospective study. Chin J Endocrinol

23.

Metab 2001;17:131-4. 23. Nathan DM , Davidson MB , DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-9.

24.

Alberti KG , Zimmet P. , Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention . Diabet Med 2007;24:451-63.

25.

National Institute for Health and Clinical Excellence. Guideline CG11 Fertility. Available at http://www.nice.org.uk/guidance/CG11/guidance/pdf/English (accessed March 2007).

26.

American Association of Clinical Endocrinologists. Position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Available at http://www.aace.com/pub/pdf/guidelines/PCOSpositionstatement.pdf (accessed October 2007)

27.

Evans JM , Donnelly LA , Emslie-Smith AM et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-05.

28.

Bowker SL , Majumdar SR , Veugelers P. , Johnson JA Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006 ;29:254-8.

29.

Nathan DM , Buse JB , Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21 and Diabetes Care 2006; 29:1963-72.